21 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
promising oncology drugs is a cornerstone of our culture and led to four of our product candidates advancing into the clinic, including azenosertib
PRE 14A
priy3z i0bo
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
iphkjl
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
3ftc6o 7tajiwkn86
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
DEF 14A
pgzvol
23 Apr 21
Definitive proxy
4:05pm